Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.

Anthony V D'Amico Wanling XieElizabeth McMahonMarian LoffredoShana MedeirosDavid JosephJim DenhamParvesh KumarGlenn BubleyMolly SullivanRichard HellwigJuan Carlos VeraRolf FreterW Jeffrey BakerJeffrey Y WongAndrew A RenshawPhilip W Kantoff

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Adding docetaxel to ADT + RT did not prolong OS in men with unfavorable-risk PC, but decreased RT-induced cancer incidence, and may prolong OS in the subgroup of men with a PSA < 4 ng/mL by reducing PC-specific mortality.

Keyphrases

prostate cancer
radical prostatectomy
risk factors
papillary thyroid
locally advanced
cardiovascular events
randomized controlled trial
clinical trial
type diabetes
diabetic rats
coronary artery disease
oxidative stress
study protocol
bone marrow
drug induced
rectal cancer
phase iii
chemotherapy induced